Skip to main content

Development of Novel Genomic Blood Biomarkers for Neurodegenerative Diseases

Buy Article:

$63.00 plus tax (Refund Policy)


Genomic blood biomarkers hold great promise for development of novel clinical and therapeutic approaches in patients with neurodegenerative diseases. Such biomarkers could prove invaluable in early disease diagnosis, monitoring of disease progression, or assessment of response to therapy. More importantly, they could be helpful in search for disease-modifying new therapies which are very much needed in modern approaches to treatment of neurodegenerative diseases, serving as surrogate endpoints in clinical trials. However, when performing expression profiling experiments aimed at discovery of new biomarker genes, standard operating procedures regarding sample collection, microarray methodology, and statistical analysis need to be fully developed and strictly adhered to. Several studies performed on patients with multiple sclerosis, Huntington's, Parkinson's and Alzheimer's disease offer promise that such approaches might prove useful in clinical practice. Crucial for successful application of any genomic biomarker will be confirmation in multiple independent patient cohorts and correlation of the improvement in biomarker endpoint with clinical improvement in longitudinal patient studies.

Keywords: (akynesia); Alzheimer's Disease; Biomarker; DNA fragmentation factor-45; Huntington Disease; Huntinngton's Disease Rating Scale; LRPPRC; MMChip; PBMC; PCR; Parkinson's Disease; RNA extraction; SORL1; STRL 22; amyloid precursor protein; apoptosis; bradykinesia; cAMP; cDNA microarray technology; cell extraction; genomics; high-throughput transcriptomic analysis; immunomodulatory therapy; interferon therapy; microarray; multiple sclerosis; myelin antigens; neurodegenerative disease; real-time PCR; ubiquitin-proteasome pathway

Document Type: Research Article


Publication date: 2010-12-01

More about this publication?
  • CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more